202,630 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 202,630 shares of the company's stock, valued at approximately $4,900,000. Jefferies Financial Group Inc. owned about 0.09% of Hims & Hers Health at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. increased its position in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. raised its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $38,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $2.58 during mid-day trading on Thursday, reaching $58.54. 56,289,776 shares of the company's stock traded hands, compared to its average volume of 19,095,021. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The stock has a market cap of $13.10 billion, a P/E ratio of 133.05 and a beta of 1.84. The business has a 50-day simple moving average of $34.36 and a 200 day simple moving average of $33.16.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The firm's revenue for the quarter was up 110.7% on a year-over-year basis. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the sale, the insider now directly owns 8,007 shares in the company, valued at approximately $230,441.46. The trade was a 21.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at approximately $5,692,221.49. This trade represents a 56.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 563,973 shares of company stock valued at $21,951,757 in the last ninety days. 13.71% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $61.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $37.67.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.